Cleo Diagnostics (ASX:COV) Accounts Receivable : A$0.08 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Cleo Diagnostics's accounts receivables for the quarter that ended in Dec. 2024 was A$0.08 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Cleo Diagnostics's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was A$0.05.

Cleo Diagnostics Accounts Receivable Historical Data

The historical data trend for Cleo Diagnostics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Accounts Receivable Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Jun24

Accounts Receivable

0.03

0.06

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Receivable	0.01	0.03	0.16	0.06	0.08

Cleo Diagnostics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Cleo Diagnostics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Cleo Diagnostics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.083	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Cleo Diagnostics's accounts receivable are only considered to be worth 75% of book value:

Cleo Diagnostics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7.311	+	0.75 * 0.083	+	0.5 * 0	-	0.448
-	0	-	0)	/	128.500
=	0.05

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Cleo Diagnostics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics Headlines

No Headlines